[18F]F-AraG
Tier C — Watch / trade[18F]F-AraG
Targets：Deoxycytidine kinase
Brand：VisAcT
Indications (approved)：Alzheimer's disease, Renal cell carcinoma, Solid tumour, Non-small cell lung cancer, COVID-19, Melanoma, HIV infection, Head and neck squamous cell carcinoma
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| [18F]F-AraG | 1268848-88-9 | - |
| [18F]F-AraG-001 | 144588-13-6 | N-(9-((2R,3R,4S,5R)-3-hydroxy-4-(trityloxy)-5-((trityloxy)methyl)tetrahydrofuran-2-yl)-6-(4-nitrophenethoxy)-9H-purin-2-yl)acetamide |
| [18F]F-AraG-002 | 1268848-85-6 | (2R,3R,4R,5R)-2-(2-acetamido-6-(4-nitrophenethoxy)-9H-purin-9-yl)-4-(trityloxy)-5-((trityloxy)methyl)tetrahydrofuran-3-yl trifluoromethanesulfonate |
| [18F]F-AraG-003 | 1268848-94-7 | - |
Frequently asked questions
What are the approved indications of [18F]F-AraG?
Approved indications include: Alzheimer's disease, Renal cell carcinoma, Solid tumour, Non-small cell lung cancer, COVID-19, Melanoma, HIV infection, Head and neck squamous cell carcinoma.
When does the [18F]F-AraG patent expire?
No public expiry year is available for [18F]F-AraG yet; this page updates once verified.
How many synthesis routes are recorded for [18F]F-AraG?
1 synthesis routes are recorded; the shortest is 3 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy [18F]F-AraG intermediates?
All intermediates in [18F]F-AraG routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for [18F]F-AraG intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09